title: Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.
abstract: The mortality from colorectal cancer has not changed appreciably in the last 30 years and new treatment avenues, such as immunotherapy, are being explored. 105AD7 is a form of active specific immunotherapy that aims to stimulate specific T-cells to target tumour specific antigens on colorectal cancer cells. Results indicate that the cancer vaccine 105AD7 is non-toxic and is capable of stimulating T-cells to target tumour specific antigens, become activated, and kill tumour cells by apoptosis. These immune responses have no effect on survival on a cohort of immunosuppressed patients with advanced disease, but results from a case-control study in patients with minimal residual disease suggest they may confer a slight survival advantage on patients receiving 105AD7.
authors.affiliation: charles.maxwell-armstrong@talk21.com
authors.forename: Charles
authors.initials: C
authors.lastname: Maxwell-Armstrong
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017209:Apoptosis; D015179:Colorectal Neoplasms / Q000276:immunology / Q000628:therapy*; D004311:Double-Blind Method; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: C405618:105AD7 antibody; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal